

Debra J H Mathews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740232/publications.pdf>

Version: 2024-02-01

64
papers

1,848
citations

394421

19
h-index

289244

40
g-index

65
all docs

65
docs citations

65
times ranked

3618
citing authors

#	ARTICLE	IF	CITATIONS
1	The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. <i>American Journal of Human Genetics</i> , 2015, 97, 199-215.	6.2	574
2	Scientific and Ethical Issues Related to Deep Brain Stimulation for Disorders of Mood, Behavior, and Thought. <i>Archives of General Psychiatry</i> , 2009, 66, 931.	12.3	159
3	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , 2021, 16, 1398-1408.	4.8	134
4	Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence. <i>Stem Cells</i> , 2009, 27, 2312-2319.	3.2	109
5	Cell-based interventions for neurologic conditions. <i>Neurology</i> , 2008, 71, 288-293.	1.1	63
6	Human embryo research, stem cell-derived embryo models and in vitro gametogenesis: Considerations leading to the revised ISSCR guidelines. <i>Stem Cell Reports</i> , 2021, 16, 1416-1424.	4.8	59
7	Pluripotent Stem Cell-Derived Gametes: Truth and (Potential) Consequences. <i>Cell Stem Cell</i> , 2009, 5, 11-14.	11.1	55
8	Opinions about new reproductive genetic technologies: Hopes and fears for our genetic future. <i>Fertility and Sterility</i> , 2005, 83, 1612-1621.	1.0	42
9	Beyond Consent in Research. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2014, 23, 361-368.	0.8	41
10	Geneticists' views on science policy formation and public outreach. <i>American Journal of Medical Genetics, Part A</i> , 2005, 137A, 161-169.	1.2	36
11	The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1-9.	4.3	34
12	Genome Editing Technologies and Human Germline Genetic Modification: The Hinxton Group Consensus Statement. <i>American Journal of Bioethics</i> , 2015, 15, 42-47.	0.9	34
13	Patients' Attitudes toward the Donation of Biological Materials for the Derivation of Induced Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2014, 14, 9-12.	11.1	33
14	Choices for return of primary and secondary genomic research results of 790 members of families with Mendelian disease. <i>European Journal of Human Genetics</i> , 2017, 25, 530-537.	2.8	31
15	Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 2368-2377.	1.6	31
16	Freedom and Responsibility in Synthetic Genomics: The Synthetic Yeast Project. <i>Genetics</i> , 2015, 200, 1021-1028.	2.9	29
17	Access to Stem Cells and Data: Persons, Property Rights, and Scientific Progress. <i>Science</i> , 2011, 331, 725-727.	12.6	28
18	CRISPR: A path through the thicket. <i>Nature</i> , 2015, 527, 159-161.	27.8	26

#	ARTICLE	IF	CITATIONS
19	Deep brain stimulation, personal identity and policy. <i>International Review of Psychiatry</i> , 2011, 23, 486-492.	2.8	25
20	Patients' perspectives on the derivation and use of organoids. <i>Stem Cell Reports</i> , 2021, 16, 1874-1883.	4.8	23
21	Stem Cell Research Ethics: Consensus Statement on Emerging Issues. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 843-848.	0.7	19
22	SCIENCE AND LAW: Integrity in International Stem Cell Research Collaborations. <i>Science</i> , 2006, 313, 921-922.	12.6	17
23	Unintended Changes in Cognition, Mood, and Behavior Arising from Cell-Based Interventions for Neurological Conditions: Ethical Challenges. <i>American Journal of Bioethics</i> , 2009, 9, 31-36.	0.9	17
24	Ethics and Collateral Findings in Pragmatic Clinical Trials. <i>American Journal of Bioethics</i> , 2020, 20, 6-18.	0.9	16
25	Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing. <i>CRISPR Journal</i> , 2020, 3, 332-349.	2.9	15
26	A Conceptual Model for the Translation of Bioethics Research and Scholarship. <i>Hastings Center Report</i> , 2016, 46, 34-39.	1.0	14
27	Revisiting Respect for Persons in Genomic Research. <i>Genes</i> , 2014, 5, 1-12.	2.4	13
28	Physicians' perspectives regarding pragmatic clinical trials. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 499-506.	1.4	12
29	GIST: A web tool for collecting gene information. <i>Physiological Genomics</i> , 1999, 1, 75-81.	2.3	11
30	Patents and Misplaced Angst: Lessons for Translational Stem Cell Research from Genomics. <i>Cell Stem Cell</i> , 2013, 12, 508-512.	11.1	11
31	The Therapeutic "Misconception": An Examination of its Normative Assumptions and a Call for its Revision. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2018, 27, 154-162.	0.8	11
32	Risk perception before and after presymptomatic genetic testing for Huntington's disease: Not always what one might expect. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 1140-1147.	1.2	10
33	Genomics in the era of COVID-19: ethical implications for clinical practice and public health. <i>Genome Medicine</i> , 2020, 12, 95.	8.2	9
34	Ethical, legal, and social issues in the Earth BioGenome Project. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2115859119.	7.1	8
35	Resisting the Tide of Professionalization: Valuing Diversity in Bioethics. <i>American Journal of Bioethics</i> , 2005, 5, 44-45.	0.9	7
36	Patients' Views About the Disclosure of Collateral Findings in Pragmatic Clinical Trials: a Focus Group Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 3436-3442.	2.6	7

#	ARTICLE	IF	CITATIONS
37	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. <i>Oncologist</i> , 2020, 25, 78-86.	3.7	7
38	Artificial Intelligence in Service of Human Needs: Pragmatic First Steps Toward an Ethics for Semi-Autonomous Agents. <i>AJOB Neuroscience</i> , 2020, 11, 120-127.	1.1	7
39	Whether, when, and how to communicate genetic risk to minors: "I wanted more information but I think they were scared I couldn't handle it". <i>Journal of Genetic Counseling</i> , 2021, 30, 237-245.	1.6	7
40	Family Communication Patterns and Challenges of Huntington's Disease Risk, the Decision to Pursue Presymptomatic Testing, and Test Results. <i>Journal of Huntington's Disease</i> , 2020, 9, 265-274.	1.9	6
41	Secondary Use of Patient Tissue in Cancer Biobanks. <i>Oncologist</i> , 2019, 24, 1577-1583.	3.7	5
42	Stakeholder perspectives regarding pragmatic clinical trial collateral findings. <i>Learning Health Systems</i> , 2020, 5, e10245.	2.0	5
43	Promoting justice in stem cell intellectual property. <i>Regenerative Medicine</i> , 2011, 6, 79-84.	1.7	4
44	Enhancing Autonomy in Biobank Decisions: Too Much of a Good Thing?. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 125-138.	1.3	4
45	Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease. <i>Journal of Genetic Counseling</i> , 2018, 27, 1428-1437.	1.6	4
46	Employees' Views and Ethical, Legal, and Social Implications Assessment of Voluntary Workplace Genomic Testing. <i>Frontiers in Genetics</i> , 2021, 12, 643304.	2.3	4
47	Patients' Reactions to Letters Communicating Collateral Findings of Pragmatic Clinical Trials: a National Web-Based Survey. <i>Journal of General Internal Medicine</i> , 2022, 37, 1658-1664.	2.6	4
48	Microsatellite Markers in Biobanking: A New Multiplexed Assay. <i>Biopreservation and Biobanking</i> , 2021, 19, 438-443.	1.0	4
49	Preferences for Updates on General Research Results: A Survey of Participants in Genomic Research from Two Institutions. <i>Journal of Personalized Medicine</i> , 2021, 11, 399.	2.5	3
50	Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine. , 2014, , 67-87.		3
51	Of mice and men: skin cells, stem cells and ethical uncertainties. <i>Regenerative Medicine</i> , 2009, 4, 791-791.	1.7	2
52	A Comparative Analysis of the Governance and Use of Residual Dried Blood Spots from State Newborn Screening Programs and Neonatal Biobanks. <i>Journal of Empirical Research on Human Research Ethics</i> , 2013, 8, 22-33.	1.3	2
53	Language matters. <i>Journal of Medical Ethics</i> , 2014, 40, 733-734.	1.8	2
54	Free Will, Self-Governance and Neuroscience: An Overview. <i>Neuroethics</i> , 2018, 11, 237-244.	2.8	2

#	ARTICLE	IF	CITATIONS
55	Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 147-150.	1.7	2
56	Voluntary workplace genomic testing: wellness benefit or Pandora's box?. Npj Genomic Medicine, 2022, 7, 5.	3.8	2
57	Deep Brain Stimulation For Treatment-Resistant Neuropsychiatric Disorders. , 2011, , .		1
58	Solidarity in the Age of CRISPR. CRISPR Journal, 2018, 1, 261-263.	2.9	1
59	Ethical issues in genetics and infectious diseases research: An interdisciplinary expert review. Ethics, Medicine and Public Health, 2021, 18, 100684.	0.9	1
60	Identification and management of pragmatic clinical trial collateral findings: A current understanding and directions for future research. Healthcare, 2021, 9, 100586.	1.3	1
61	Brain Research on Morality and Cognition. , 2015, , 1151-1166.		1
62	Neuroethics: An introduction. Neurotherapeutics, 2007, 4, 523-524.	4.4	0
63	Response to Open Peer Commentaries on "Ethics and Collateral Findings in Pragmatic Clinical Trials". American Journal of Bioethics, 2020, 20, W9-W11.	0.9	0
64	When emerging biomedical technologies converge or collide. , 2017, , .		0